Exozymes (EXOZ) Competitors $12.05 -1.48 (-10.94%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock EXOZ vs. RAPP, ZYBT, MAZE, MREO, ERAS, PRTC, ORKA, SANA, SNDL, and ZVRAShould you be buying Exozymes stock or one of its competitors? The main competitors of Exozymes include Rapport Therapeutics (RAPP), Zhengye Biotechnology (ZYBT), Maze Therapeutics (MAZE), Mereo BioPharma Group (MREO), Erasca (ERAS), PureTech Health (PRTC), Oruka Therapeutics (ORKA), Sana Biotechnology (SANA), SNDL (SNDL), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. Exozymes vs. Rapport Therapeutics Zhengye Biotechnology Maze Therapeutics Mereo BioPharma Group Erasca PureTech Health Oruka Therapeutics Sana Biotechnology SNDL Zevra Therapeutics Exozymes (NASDAQ:EXOZ) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability. Do analysts recommend EXOZ or RAPP? Rapport Therapeutics has a consensus target price of $32.67, suggesting a potential upside of 194.29%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Exozymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exozymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor EXOZ or RAPP? Rapport Therapeutics received 3 more outperform votes than Exozymes when rated by MarketBeat users. CompanyUnderperformOutperformExozymesN/AN/ARapport TherapeuticsOutperform Votes375.00% Underperform Votes125.00% Does the media prefer EXOZ or RAPP? In the previous week, Rapport Therapeutics had 5 more articles in the media than Exozymes. MarketBeat recorded 6 mentions for Rapport Therapeutics and 1 mentions for Exozymes. Rapport Therapeutics' average media sentiment score of 0.72 beat Exozymes' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exozymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EXOZ or RAPP more profitable? Company Net Margins Return on Equity Return on Assets ExozymesN/A N/A N/A Rapport Therapeutics N/A N/A N/A Which has preferable valuation and earnings, EXOZ or RAPP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExozymesN/AN/AN/AN/AN/ARapport TherapeuticsN/AN/A-$34.79M-$13.84-0.80 SummaryRapport Therapeutics beats Exozymes on 6 of the 6 factors compared between the two stocks. Get Exozymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetricExozymesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.83M$2.93B$5.41B$7.70BDividend YieldN/A1.91%5.44%4.33%P/E RatioN/A30.4322.1818.31Price / SalesN/A478.52397.31107.09Price / CashN/A168.6838.2034.62Price / BookN/A3.786.834.25Net IncomeN/A-$72.06M$3.20B$247.51M7 Day Performance11.16%11.17%5.76%6.86%1 Month Performance-4.06%-4.87%-4.32%-2.95%1 Year PerformanceN/A-18.74%17.88%5.17% Exozymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZExozymesN/A$12.05-10.9%N/AN/A$100.83MN/A0.0029Gap UpRAPPRapport Therapeutics1.84 of 5 stars$11.24-1.3%$32.67+190.8%N/A$408.94MN/A-0.81N/AZYBTZhengye BiotechnologyN/A$8.62+10.2%N/AN/A$406.57M$189.75M0.00278MAZEMaze TherapeuticsN/A$9.11-4.6%$25.67+181.7%N/A$398.98M$167.50M0.00121MREOMereo BioPharma Group1.8565 of 5 stars$2.52-1.8%$7.71+206.7%-8.6%$398.45M$1M-41.7740News CoverageERASErasca3.1413 of 5 stars$1.41-1.1%$4.83+244.0%-25.5%$398.27MN/A-1.69120Positive NewsPRTCPureTech Health2.5268 of 5 stars$17.34-2.1%$45.00+159.5%-38.0%$396.67M$3.33M0.00100ORKAOruka Therapeutics2.8916 of 5 stars$10.42-1.5%$39.86+282.6%N/A$390.55MN/A-1.67N/ASANASana Biotechnology2.2611 of 5 stars$1.73+0.9%$10.80+526.1%-79.4%$390.42MN/A-1.24380Analyst ForecastSNDLSNDL2.9966 of 5 stars$1.47+3.2%$3.63+147.4%-26.0%$384.97M$920.45M-4.73580Upcoming EarningsZVRAZevra Therapeutics2.606 of 5 stars$7.09-2.2%$22.29+214.5%+58.8%$383.20M$23.61M-3.5920 Related Companies and Tools Related Companies Rapport Therapeutics Competitors Zhengye Biotechnology Competitors Maze Therapeutics Competitors Mereo BioPharma Group Competitors Erasca Competitors PureTech Health Competitors Oruka Therapeutics Competitors Sana Biotechnology Competitors SNDL Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exozymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exozymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXOZ Stock Free EXOZ Stock Alerts